Tema Oncology ETF
CANC
6 hedge funds and large institutions have $54.6M invested in Tema Oncology ETF in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
1,013% more capital invested
Capital invested by funds: $4.9M → $54.6M (+$49.7M)
41.98% more ownership
Funds ownership: 6.26% → 48.23% (+42%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$42.9M |
| 2 |
Jane Street
New York
|
+$1.03M |
| 3 |
LPL Financial
San Diego,
California
|
+$262K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
-$630K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$17.4K |
| 3 |
PS
Principal Securities
Des Moines,
Iowa
|
-$1.44K |
CANC Hedge Fund Activity: Q4 2025 in Review
6 of the 8,282 institutional investors tracked by Wall St. Rank reported a position in Tema Oncology ETF (CANC) for Q4 2025, worth a combined $54.6M — up 1,013% from $4.9M a quarter earlier.
Fund positioning in CANC was balanced in Q4 2025: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $42.9M. The largest seller was Flow Traders U.S., exiting entirely with an estimated $630K sold.
- 6 institutional investors held Tema Oncology ETF (CANC) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $54.6M of Tema Oncology ETF stock for Q4 2025, up 1,013% quarter-over-quarter.
- 3 funds opened new Tema Oncology ETF positions in Q4 2025 and 3 closed out, a net change of 0 holders.
- The largest Tema Oncology ETF buyer in Q4 2025 was Thrivent Financial for Lutherans, an estimated $42.9M added.
- The largest Tema Oncology ETF seller in Q4 2025 was Flow Traders U.S., an estimated $630K sold.
Based on aggregated 13F filings for Q4 2025.